|Grant ID: RR150039|
Recruitment of First-Time, Tenure-Track Faculty Members
National Cancer Institute/National Institutes of Health
April 20, 2015
One of the hallmarks of leukemia is unlimited division of blood progenitor cells that lack the capacity to mature into functional cells. Exploring why these cells fail to mature could help researchers develop new therapies to treat the disease.
A scientist at the University of Texas M.D. Anderson Cancer Center is hoping that her studies on the role of epigenetics in acute myeloid leukemia can aid in developing new treatments for people diagnosed with this deadly disease. Epigeneticist Margarida I. Albuquerque Almeida Santos was recruited in 2015 with the help of a First-Time Tenure-Track Award from CPRIT. She joined the Department of Epigenetics and Molecular Carcinogenesis from the National Cancer Institute where she was a postdoctoral fellow.
Almeida Santos focuses on a type of acute myeloid leukemia common in children and older adults. In this disease, blood cells called blasts multiply but can’t mature into functional blood cells. Patients feel tired and weak and are susceptible to infections. Although some can be treated with chemotherapy and a stem cell transplant, the treatments are toxic and not all patients are eligible.